Metformin could one day be used to treat malignant tumors

January 16, 2018, Agency for Science, Technology and Research (A*STAR), Singapore

A*STAR researchers have provided strong evidence, using patient tumor grafts, that metformin, a common diabetes drug, might help fight colorectal cancer in humans.

Metformin's potential as a tumor-suppressing agent, to prevent the growth of breast, colon, lung and prostate cancers, has been demonstrated in pre-clinical studies. However, the experimental models used in these studies do not accurately recreate the natural manifestations of the disease, and require toxic levels of to demonstrate beneficial effects.

Min-Han Tan and a group of researchers from A*STAR's Institute of Bioengineering and Nanotechnology (IBN), the Biological Resource Centre, and the Genome Institute of Singapore, with collaborators from hospitals across Singapore, have now tested metformin's cancer-fighting abilities on a model of that is more representative of how the disease appears in humans.

The team took samples of from two patients and implanted them in mice, then assessed how the tumors responded to metformin as well as 5-fluorouracil, the current front-line treatment for colorectal cancer.

They found that metformin inhibited by at least 50 per cent after 24 days and, when combined with 5-fluorouracil, inhibited the tumor grafts from one patient by 85 per cent. The experiments used concentrations of metformin equivalent to that used to treat diabetes in humans.

In previous studies, scientists typically injected cancer cells into host animals rather than transplanting tissue directly. In these models, high glucose, insulin, and growth factor levels are needed to establish cell cultures for injection. Tan's group suspects that this artificial environment meant previous studies needed higher levels of metformin to stunt tumor growth as, in this study, they were able to demonstrate response using therapeutic doses of the drug: "We tested a wide range of concentrations down to the physiological," says Tan. "It was important to show that there was a response at that level, as many studies have not documented that."

The IBN-led collaboration discovered that metformin enacted its therapeutic benefits by activating a cellular pathway implicated in the inhibition of cancer, and by reducing cancer cell oxygen consumption. Using next-generation genetic sequencing, the team also provided evidence that direct patient tissue grafts in mice retain the genetic, molecular, and tissue features of the original tumor—making them ideal platforms to study colorectal cancer and its treatment.

It's believed that this is the first investigation into metformin and colorectal cancer using patient grafts. Tan says that future studies could shed light on metformin's relevance as a therapeutic agent for cancer: "Our study shows that metformin has a possible activity against colorectal , using gold-standard materials, and provides a mechanism to explain this. Further clinical trials are now needed."

Explore further: Diabetes drug metformin inhibits multidrug-resistant breast cancer

More information: Nur-Afidah Mohamed Suhaimi et al. Metformin Inhibits Cellular Proliferation and Bioenergetics in Colorectal Cancer Patient–Derived Xenografts, Molecular Cancer Therapeutics (2017). DOI: 10.1158/1535-7163.MCT-16-0793

Related Stories

Diabetes drug metformin inhibits multidrug-resistant breast cancer

December 6, 2017
The drug metformin, typically prescribed to treat type 2 diabetes, keeps breast cancer cells from developing multiple drug resistance (MDR) and can reverse MDR after it¹s appeared, according to a study published December ...

Metformin confers anti-tumor immunity by reactivating exhausted CD8T lymphocytes

February 24, 2016
Anti-cancer effect of tumor infiltrating CD8+T lymphocyte (CD8TIL) is suppressed by interaction between immune-checkpoint molecules such as PD-1 and CTLA-4 expressed on CD8TIL and their ligands expressed on cancer cells, ...

More side effects with CRT plus metformin in head, neck cancer

May 7, 2017
(HealthDay)—Patients with advanced head and neck cancer undergoing chemoradiotherapy (CRT) and receiving metformin experience more side effects than patients not on metformin, according to research published online April ...

Diabetes drug takes aim at cancer's fuel source

January 25, 2017
In the last three years, researchers have shown that diabetic patients with head and neck cancer, may have better outcomes than non-diabetic patients when they are taking the drug metformin for their diabetes. In order to ...

Study: Metformin for breast cancer less effective at higher glucose concentrations

October 24, 2013
A University of Colorado Cancer Center study published online this month in the journal Cell Cycle shows that breast cancer cell growth, motility and aggression is promoted by excess glucose, as experienced by patients with ...

Recommended for you

Researchers use a molecular Trojan horse to deliver chemotherapeutic drug to cancer cells

February 23, 2018
A research team at the University of California, Riverside has discovered a way for chemotherapy drug paclitaxel to target migrating, or circulating, cancer cells, which are responsible for the development of tumor metastases.

An under-the-radar immune cell shows potential in fight against cancer

February 23, 2018
One of the rarest of immune cells, unknown to scientists a decade ago, might prove to be a potent weapon in stopping cancer from spreading in the body, according to new research from the University of British Columbia.

Study tracks evolutionary transition to destructive cancer

February 23, 2018
Evolution describes how all living forms cope with challenges in their environment, as they struggle to persevere against formidable odds. Mutation and selective pressure—cornerstones of Darwin's theory—are the means ...

Lab-grown 'mini tumours' could personalise cancer treatment

February 23, 2018
Testing cancer drugs on miniature replicas of a patient's tumour could help doctors tailor treatment, according to new research.

Putting black skin cancer to sleep—for good

February 22, 2018
An international research team has succeeded in stopping the growth of malignant melanoma by reactivating a protective mechanism that prevents tumor cells from dividing. The team used chemical agents to block the enzymes ...

Cancer risk associated with key epigenetic changes occurring through normal aging process

February 22, 2018
Some scientists have hypothesized that tumor-promoting changes in cells during cancer development—particularly an epigenetic change involving DNA methylation—arise from rogue cells escaping a natural cell deterioration ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.